22UA:FRA
BioNTech SE - ADR
78,10 €
arrow_downward
-1,88%(-1,50) 1D
16 қаз., 22:00:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
80,15 €
High
81,25 €
Low
78,10 €
Mkt. cap
22,03 млрд
Avg. vol.
1,43 мың
Volume
602,00
52-wk high
105,50 €
52-wk low
68,00 €
No. of employees
8 мың
Open
80,15 €
High
81,25 €
Low
78,10 €
Mkt. cap
22,03 млрд
Avg. vol.
1,43 мың
Volume
602,00
52-wk high
105,50 €
52-wk low
68,00 €
No. of employees
8 мың
News stories
From web sources and news partners
24/7 Wall St.
·
13 сағат бұрын
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Pluang
·
2 күн бұрын
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
2 күн бұрын
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TipRanks
·
3 күн бұрын
BioNTech Presses Ahead With BNT113 Cancer Trial After Initial Endpoint Miss
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR